



February 13, 2017

Mirati Therapeutics To Present At Leerink Partners 6th Annual Global Healthcare Conference

SAN DIEGO, Feb. 13, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that Charles M. Baum, M.D., Ph.D., President and CEO of Mirati, will provide a corporate overview during a fireside chat presentation at the Leerink Partners 6th Annual Global Healthcare Conference on Thursday, February 16, 2017 at 2:30 p.m. ET (11:30am PT) in New York City.

An audio webcast of the presentation will be accessible on the "Investors" page of Mirati's corporate website at www.mirati.com. A replay of the presentation will be available at the same location for 60 days following the conference.

About Mirati Therapeutics

Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of targeted oncology products intended to treat specific genetic and epigenetic drivers of cancer in selected subsets of cancer patients with unmet needs. Our clinical pipeline consists of three product candidates: glesatinib, sitravatinib and mocetinostat. Both glesatinib and sitravatinib are orally bioavailable, spectrum-selective kinase inhibitors with distinct target profiles that are in development for the treatment of patients with NSCLC and other solid tumors. Glesatinib targets the *MET* receptor tyrosine kinase family and is in Phase 2 clinical development. Sitravatinib targets *RET* rearrangements, *CHR4q12* amplifications (encompassing *KDR*, *PDGFRA* and *KIT*), and *CBL* and *AXL* mutations, and is in Phase 1b clinical development. Sitravatinib is also being evaluated in combination with nivolumab, a PD-1 inhibitor, for the treatment of patients with NSCLC. Sitravatinib is a potent inhibitor of the TAM (*Tyro*, *Axl*, *Mer*) and split (*KDR*, *KIT*) tyrosine kinase families, which regulate multiple stages in the cancer immunity cycle and are thought to enhance anti-tumor immunity by improving the efficacy of immune checkpoint inhibitors (anti PD-1/PD-L1).

Our third product candidate is mocetinostat, an orally bioavailable, spectrum-selective Class 1 histone deacetylase inhibitor. Mocetinostat is in Phase 1b/2 clinical development in combination with durvalumab, MedImmune's anti-PD-L1 immune checkpoint inhibitor, for the treatment of patients with NSCLC. More information is available at www.mirati.com.



To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/mirati-therapeutics-to-present-at-leerink-partners-6th-annual-global-healthcare-conference-300406381.html>

SOURCE Mirati Therapeutics, Inc.